Primary Cardiac Lymphoma: Italian Multicenter Experience

Who May Qualify: - Diagnosis of PCL (any histotype) defined as an extranodal lymphoma involving only the heart with possible involvement of the pericardium. - Age ≥18 years. - Diagnosis diagnosed by tissue sample (biopsy-confirmed). Cytofluorimetry analysis of pericardial fluid showing phenotypic features consistent with a primary cardiac lymphoma is permitted if a biopsy sample is not feasible/available for diagnosis; monoclonality is not accepted as a surrogate for diagnosis. - Date of diagnosis: from 1st January 2000 to 31st December 2020. - Only patients treated in first-line with chemoimmunotherapy regimens including an anti-CD20 monoclonal antibody are eligible for the study. - Signed written willing to sign a consent form (in case of unreachable subject please see chapter 11.2) Who Should NOT Join This Trial: - Secondary cardiac involvement from lymphoma; primary mediastinal lymphoma with pericardial infiltration or other lymphomas with involvement of the pericardium/the heart by contiguity and primary effusion lymphoma are not included in this study. - Patients treated with chemotherapy regimens that did not include an anti-CD20 monoclonal antibody as first-line therapy. - Refuse to sign a written willing to sign a consent form Always talk to your doctor about whether this trial is right for you.